Articles by Andrew Moreno
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Belantamab mafodotin plus pomalidomide-dexamethasone showed greater efficacy to pomalidomide-bortezomib-dexamethasone.
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Zilovertamab vedotin plus R-GemOx shows promise in R/R DLBCL, with RP2D set at 1.75 mg/kg per WaveLINE-003 phase 2/3 trial.
The MANIFEST-2 trial compares pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAK-inhibitor-naive myelofibrosis.
The global phase 3 randomized study is the primary evidence in an sBLA for daratumumab and hyaluronidase in high-risk SMM.
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
This agent also has Orphan Drug designation from the EMA and a phase III study is currently enrolling patients.
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
In the US, a BLA submitted for these two particular combinations is currently under review at the FDA.
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.